Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience reported Q3 FY26 revenue of $118.4M (+23% Y/Y), with gross margin rising 120 bps sequentially to 52.8%. The company raised FY26 revenue guidance to $456M–$457M (+$12M at the midpoint) and guided Q4 revenue to $123M–$124M (~+25% Y/Y at the midpoint), citing sustained demand and AI-enabled drug discovery as a primary growth driver. Management reiterated its path to adjusted EBITDA breakeven in Q4 FY26, supported by planned OpEx reductions (>$5M in Q4 excluding one-time transition costs) and ongoing manufacturing productivity gains (60% lower costs and 70% less waste over three years).

Analysis

TWST is turning the market narrative from "nice growth" to "operating leverage optionality," which should re-rate the stock if it can prove Q4 breakeven without slowing the top line. The clear winners are not just TWST shareholders but also adjacent synthetic biology / diagnostic workflow vendors that benefit from higher probe counts and faster iteration cycles; the losers are smaller gene-synthesis and reagent suppliers that lack scale or software integration, because TWST is using process automation to pull more of the wallet into one platform.

The key second-order effect is competitive: the company is moving from a commodity DNA supplier to a workflow layer, which raises switching costs and can compress gross margin for rivals that still sell discrete inputs. But the customer mix is concentrated, especially in NGS, so any slowdown in a handful of MRD or diagnostics accounts would show up quickly in the next 1-2 quarters. The important catalyst window is the November FY27 guide: if management can show AI orders are converting into revenue with less lag and OpEx falls as promised, the market may extend the multiple; if not, the stock likely de-rates back to "promising but unprofitable platform."

Consensus is probably underestimating how much of the growth is coming from repeat workflows rather than one-off experiments, but it may be overestimating how linear that becomes. The bullish case depends on three things that can all fail: AI customer retention, sustained diagnostic volume growth, and margin expansion from internalized enzyme supply. Any evidence that AI orders are still pilot-heavy, or that EBITDA breakeven slips in Q4, would falsify the thesis quickly.

Key Decisions for Investors

• Go long TWST on any post-print consolidation; best entry is on a 3-5% pullback with a 3-6 month horizon into the November FY27 guide. Risk/reward is attractive if the market re-rates on visible operating leverage; thesis breaks if Q4 EBITDA breakeven slips or FY27 growth guidance comes in below the current enthusiasm.
• Buy TWST Jan-2027 call spreads rather than outright calls to express the AI/order-conversion thesis with defined downside. The setup works if the stock continues to re-rate into FY27 guidance, but should be sized for headline volatility because customer concentration can create sharp drawdowns on any miss.
• Pair trade: long TWST / short a broad life-science tools proxy or basket over the next 1-3 months. The relative edge is TWST-specific execution and software-like workflow lock-in; the short leg should protect against a market-wide multiple reset if biotech sentiment weakens.
• Set an alert on FY27 guidance and Q4 margin commentary; if management fails to show sequential OpEx improvement or raises growth without margin support, take profits aggressively. The stock is most vulnerable if the market concludes revenue quality is still too lumpy to support a premium multiple.